Does First Year MRI and Clinical Activity Correlate with Long Term Clinical Response to Glatiramer Acetate in Multiple Sclerosis Patients? (P01.194)

CONCLUSIONS: Patients on GA after one to two years harbor new brain MRI T1Gd(+) and T2H lesions, which decline over the third year. The significance of new and enhancing MRI lesions and their predictive value over 5 years of follow up will be presented.Supported by: Teva.Disclosure: Dr. Karmon has nothing to disclose. Dr. Ramanathan has received personal compensation for activities with Serono Inc., Biogen Idec, Allergan, Inc., Netezza, Pfizer, Novartis, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation and the National Institutes of Health as a consultant. Dr. Ramanathanhas received personal compensation in an editorial capacity for American Association of Pharmaceutical Scientists. Dr. Ramanathan has received research support from Serono Inc., Biogen Idec, Allergan Inc., Netezza, Pfizer, Novartis, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health. Dr. Weinstock-Guttman has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Serono Inc., Novartis, Pfizer, Inc., Teva Neuroscience and Genentech, Inc. as a speaker and/or participant on an advisory board. Dr. Weinstock-Guttman has received research support from the National Multiple Sclerosis Society, the National Institutes of Health, ITN, Teva Neuroscience, Biogen Idec, Serono Inc., Aspreva-Roche, Acorda Therapeutics & Cognition, Shire Pharmaceuticals Group and Nova...
Source: Neurology - Category: Neurology Authors: Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research